{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:34:59Z","timestamp":1791005699264,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"ANRS-MIE"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doravirine is licensed in patients living with HIV (PWH) harbouring no prior resistance to any NNRTIs. We aimed to evaluate in real life the efficacy of doravirine with prior NNRTI virological failure and NNRTI resistance-associated mutations (RAMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational study included PWH switched to a doravirine-containing regimen between 30 September 2019 and 1 May 2022, with an HIV-1 RNA of \u226450\u2005copies\/mL and past NNRTI-RAMs. The main outcome was the proportion of participants with virological failure at Week 48 and Week 96. Secondary outcomes evaluated the rate of viral suppression and transient virological blip, RAMs in the case of virological failure and side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 102 patients were analysed, mostly men (63%), with a median age of 59\u2005years (IQR 51\u201363). The median time since HIV-1 diagnosis was 26\u2005years (IQR 16\u201331), on ART for 22\u2005years (IQR 14\u201326) and virally suppressed for 7\u2005years (IQR 1\u201311).<\/jats:p>\n                    <jats:p>Of the patients analysed, 25\/102 (25%) had documented historical RAMs to doravirine, 9\/25 (36%) showing possible resistance and 16\/25 (64%) showing major resistance. The resistance profile primarily (21\/23) consisted of the K103N, Y181C and\/or G190A\/E reverse transcriptase substitutions. Median time since the last detection of NNRTI-RAMs was 12\u2005years (5\u201317). Over 2\u2005years follow-up, no virological failure occurred, neither at Week 48 (0\/87; 0%) nor Week 96 (0\/86; 0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first real-world study to provide new insight about the use of doravirine-containing regimens as a treatment in long-term suppressed patients whose viruses harboured specific NNRTI-RAMs in their history.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae481","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T15:26:20Z","timestamp":1735572380000},"page":"810-816","source":"Crossref","is-referenced-by-count":7,"title":["No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-0010","authenticated-orcid":false,"given":"B","family":"Abdi","sequence":"first","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Saliba","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3723-4142","authenticated-orcid":false,"given":"M","family":"Wirden","sequence":"additional","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Faycal","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Cocherie","sequence":"additional","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-0101","authenticated-orcid":false,"given":"R","family":"Palich","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Schneider","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Seang","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Valantin","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3879-1480","authenticated-orcid":false,"given":"V","family":"Pourcher","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne University, Virology Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , 75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Katlama","sequence":"additional","affiliation":[{"name":"Sorbonne University, Infectious Diseases Department, Piti\u00e9-Salp\u00eatri\u00e8re hospital, AP-HP, Pierre Louis Institute of Epidemiology and Public Health (iPLESP), INSERM U1136 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"2025030423053903100_dkae481-B1","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2025030423053903100_dkae481-B2","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"2025030423053903100_dkae481-B3","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/S2352-3018(23)00258-8","article-title":"Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials","volume":"11","author":"Orkin","year":"2024","journal-title":"Lancet HIV"},{"key":"2025030423053903100_dkae481-B4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial","volume":"81","author":"Johnson","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025030423053903100_dkae481-B5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","article-title":"Brief report: switching to DOR\/3TC\/TDF maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial","volume":"87","author":"Kumar","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025030423053903100_dkae481-B6","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1177\/09564624231195084","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: a real-life experience","volume":"34","author":"Calza","year":"2023","journal-title":"Int J STD AIDS"},{"key":"2025030423053903100_dkae481-B7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3390\/v16040582","article-title":"Cardiometabolic differences in people living with HIV receiving integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors: implications for current ART strategies","volume":"16","author":"Vos","year":"2024","journal-title":"Viruses"},{"key":"2025030423053903100_dkae481-B8","doi-asserted-by":"publisher","first-page":"2339576","DOI":"10.1080\/25787489.2024.2339576","article-title":"Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to doravirine-based regimens in people with HIV","volume":"25","author":"Kousari","year":"2024","journal-title":"HIV Res Clin Pract"},{"key":"2025030423053903100_dkae481-B9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/QAI.0000000000003248","article-title":"Doravirine plus integrase strand transfer inhibitors as a 2-drug treatment\u2013switch strategy in people living with HIV: the real-life DORINI multicentric cohort study","volume":"94","author":"Poliseno","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025030423053903100_dkae481-B10","doi-asserted-by":"publisher","first-page":"e00326-18","DOI":"10.1128\/AAC.00326-18","article-title":"Severe renal impairment has minimal impact on doravirine pharmacokinetics","volume":"62","author":"Ankrom","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423053903100_dkae481-B11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/jcph.857","article-title":"Moderate hepatic impairment does not affect doravirine pharmacokinetics","volume":"57","author":"Khalilieh","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2025030423053903100_dkae481-B12","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423053903100_dkae481-B13","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423053903100_dkae481-B14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","article-title":"Review of doravirine resistance patterns identified in participants during clinical development","volume":"85","author":"Martin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025030423053903100_dkae481-B15","doi-asserted-by":"publisher","first-page":"2019-11-4","DOI":"10.7573\/dic.2019-11-4","article-title":"Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection","volume":"9","author":"Pham","year":"2020","journal-title":"Drugs Context"},{"key":"2025030423053903100_dkae481-B16","doi-asserted-by":"publisher","first-page":"e02223-21","DOI":"10.1128\/aac.02223-21","article-title":"Doravirine and islatravir have complementary resistance profiles and create a combination with a high barrier to resistance","volume":"66","author":"Lai","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423053903100_dkae481-B17","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1128\/AAC.02650-15","article-title":"Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423053903100_dkae481-B18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12981-023-00503-5","article-title":"Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance","volume":"20","author":"Rhee","year":"2023","journal-title":"AIDS Res Ther"},{"key":"2025030423053903100_dkae481-B19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1345\/aph.1M359","article-title":"Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents","volume":"44","author":"Adams","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2025030423053903100_dkae481-B20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1021\/acsinfecdis.9b00178","article-title":"Rational design of doravirine: from bench to patients","volume":"6","author":"Hwang","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2025030423053903100_dkae481-B21","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1097\/00002030-200111090-00016","article-title":"Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure","volume":"15","author":"Delaugerre","year":"2001","journal-title":"AIDS"},{"key":"2025030423053903100_dkae481-B22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/00002030-200405210-00008","article-title":"The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution","volume":"18","author":"Lambotte","year":"2004","journal-title":"AIDS"},{"key":"2025030423053903100_dkae481-B23","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1111\/j.1469-0691.2010.03329.x","article-title":"Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection","volume":"16","author":"Turriziani","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2025030423053903100_dkae481-B24","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s40121-022-00676-y","article-title":"HIV DNA sequencing to detect archived antiretroviral drug resistance","volume":"11","author":"Geretti","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2025030423053903100_dkae481-B25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/jac\/dkv395","article-title":"Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression","volume":"71","author":"Gantner","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025030423053903100_dkae481-B26","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025030423053903100_dkae481-B27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/infdis\/jiab413","article-title":"Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients","volume":"225","author":"Palich","year":"2022","journal-title":"J Infect Dis"},{"key":"2025030423053903100_dkae481-B28","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1097\/QAI.0000000000002153","article-title":"Efficacy and safety of doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) in treatment-naive adults with HIV-1 and transmitted nonnucleoside reverse transcriptase inhibitor resistance mutations","volume":"82","author":"Wong","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025030423053903100_dkae481-B29","author":"Brumme"},{"key":"2025030423053903100_dkae481-B30","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/jac\/dkad184","article-title":"Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure","volume":"78","author":"Brenner","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025030423053903100_dkae481-B31","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1093\/jac\/dky315","article-title":"Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia","volume":"73","author":"Rodriguez","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/810\/61439687\/dkae481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/810\/61439687\/dkae481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:05:46Z","timestamp":1741111546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/3\/810\/7954232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae481","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,15]]}}}